)

Shattuck Labs (STTK) investor relations material
Shattuck Labs The United European Gastroenterology (UEG) Congress UEG Week 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key scientific insights
DR3 is a stable, broadly expressed receptor in IBD, making it a promising therapeutic target compared to the transiently expressed TL1A ligand.
Blocking DR3 may offer superior efficacy and reduced immunogenicity versus TL1A blockade, as DR3 targeting avoids immune complex formation that drives anti-drug antibody responses.
The DR3 blocking antibody (SL325) is designed for high affinity and lacks Fc gamma receptor binding, minimizing off-target effects and residual agonism.
Preclinical studies confirmed SL325 does not induce T cell proliferation or cytokine release, supporting its antagonist profile.
No other disclosed DR3 antagonist programs are known, with technical challenges limiting competition.
Clinical development and strategy
Phase 1 trials for the DR3 antibody are ongoing, with completion expected in the first half of next year.
Plans are in place to move directly into multiple placebo-controlled phase 2 trials, including at least one in IBD.
Comparative efficacy and immunogenicity versus TL1A antibodies will be key endpoints in upcoming studies.
Data from these trials are anticipated in 2026.
Study design aims to facilitate cross-trial comparisons with existing TL1A therapies.
Market and indication landscape
TL1A/DR3 pathway is implicated in IBD, asthma, psoriatic arthritis, psoriasis, rheumatoid arthritis, and primary biliary cirrhosis.
DR3 targeting may be especially effective in diseases with persistent antigen exposure, such as IBD and RA, compared to relapsing-remitting diseases like asthma.
Major pharmaceutical companies are pursuing TL1A blockade in multiple indications, but DR3 antagonism may offer differentiation.
The antibody's broad potential across autoimmune and fibrotic diseases increases its clinical and commercial attractiveness.
No current competitors have advanced DR3 antagonists to clinical disclosure, suggesting a first-mover advantage.
Next Shattuck Labs earnings date

Next Shattuck Labs earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage